1-7 of 7
histamine h2 antagonists
Close
Sort by
Journal Articles

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Cem Akin, MD PhD, Vito Sabato, Jason Gotlib, MD MS, Mariana Castells, Michael W. Deininger, Hanneke Oude Elberink, Mark L Heaney, Paul van Daele, Deepti Radia, Massimo Triggiani, Daniel J. DeAngelo, MD, Iván Alvarez-Twose, Sigurd Broesby-Olsen, Tracy I. George, MD, Karin Hartmann, Siebenhaar Frank, Andreas Reiter, Peter Vadas, Patrizia Bonadonna, Jens P. Panse, Petra Staubach-Renz, Knut Brockow, Diamant Thaci, Hui-Min Lin, Andrew Morrison, Brenton Mar, Marcus Maurer
Journal: Blood
Blood (2019) 134 (Supplement_1): 2950.
https://doi.org/10.1182/blood-2019-126035
Published: 2019
Journal Articles

When to Suspect Systemic Mastocytosis?

Sibel Kaplan, MD, Baris Kuskonmaz, MD, özge Ulusoy Soyer, Selin Aytaç, Fatma Gümrük
Journal: Blood
Blood (2018) 132 (Supplement 1): 5826.
https://doi.org/10.1182/blood-2018-99-119809
Published: 2018
Journal Articles

Absence of Plasma Gastric Biomarker Elevations with Chronic Dosing of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Patients with Chronic Immune Thrombocytopenia in Phase 3 Trials

James B. Bussel, MD, Lee F. Allen, MD PhD, Wei Tian, PhD, David J. Kuter, MD DPhil
Journal: Blood
Blood (2018) 132 (Supplement 1): 3740.
https://doi.org/10.1182/blood-2018-99-116873
Published: 2018
Journal Articles

Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis

Philina Lee, PhD, Tracy I. George, MD, Hongliang Shi, MS, Erica K. Evans, PhD, Teghpal Singh, PhD, Anthony L Boral, MD PhD, Vanessa Rangel Miller, MS, MBA, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4783.
https://doi.org/10.1182/blood.V128.22.4783.4783
Published: 2016
Journal Articles

KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies

Ronan T Swords, MD PhD FRCPI, FRCPath, Andrew H Wei, MBBS, PhD, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPat, Anjali S. Advani, MD, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Ian D Lewis, MBBS, PhD, Peter L. Greenberg, MD PhD, Jorge E. Cortes, MD, Geoff T Yarranton, PhD, Jackie M. Walling, MBChB, PhD, Jeffrey E. Lancet, MD
Journal: Blood
Blood (2014) 124 (21): 3756.
https://doi.org/10.1182/blood.V124.21.3756.3756
Published: 2014
Journal Articles

A Murine Model of Asparaginase Allergy

Christian A. Fernandez, PhD, Colton Smith, PhD, Seth E. Karol, MD, Laura B. Ramsey, PhD, Chengcheng Liu, Ching-Hon Pui, MD, Sima Jeha, MD, William E. Evans, PharmD, Fred D. Finkelman, PhD, Mary V. Relling, PharmD
Journal: Blood
Blood (2014) 124 (21): 2295.
https://doi.org/10.1182/blood.V124.21.2295.2295
Published: 2014
Journal Articles

A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.

Andreas Hochhaus, MD, Oliver G. Ottmann, MD, STephanie Lauber, MD, Timothy Hughes, MD, Gregor Verhoef, MD, Anthony P. Schwarer, MD, Alois Gratwohl, MD, Teresa Rafferty, RN, Debra Resta, RN, Norbert Gattermann, MD
Journal: Blood
Blood (2006) 108 (11): 2703.
https://doi.org/10.1182/blood.V108.11.2703.2703
Published: 2006